In vivo evaluation of a biodegradabledonut-shaped minitablet for prolonged posterior segment drug delivery in therabbit eye model

Author(s): ChoonaraYE, Pillay V, Danckwerts MP, Carmichael TR, Meyer LC, et al.


This study focused on the in vivo evaluation of a biodegradable ganciclovir-loaded donut-shaped minitablet (DSMT) for controlled drug delivery in the New Zealand white albino rabbit eye model. Specialized tablet tooling was used to manufacture a poly(lactic-co-glycolic acid) DSMT device that was implanted into 18 rabbits through the pars plana/peripheral retina of the right eyes of each rabbit. The left eyes were used as controls. Possible adverse effects on ocular tissues were assessed by histomorphology, slit-lamp biomicroscopy, intraocular pressure (IOP) measurements, and indirect ophthalmoscopy. The ex vivo microenvironmental vitreous pH was also monitored. Rabbits were euthanized at predetermined intervals and the residual devices, vitreous humor, and ocular tissue were retrieved and stored appropriately until further analysis. The DSMT was well tolerated up to 72 days and was still visible in the superotemporal quadrant of the eye. The mean IOP range (6–8 mmHg; N=18) and changes in vitreous pH (7.25±0.01; N=3) correlated with baseline measurements. The DSMT displayed constant ganciclovir release at a rate of 2.02 μg/h maintained within the 50% effective dose for human cytomegalovirus retinitis (N=3). The design simplicity and application of the biodegradable DSMT device may provide a superior alternative for prolonged rate-controlled intraocular drug delivery.

Similar Articles

Drug delivery to the posterior segment of the eye

Author(s): Lee TWY, RobinsonJR

Development andevaluation of prolonged release topical indomethacin formulations for ocularinflammation

Author(s): AdelliGR, Balguri SP, Punyamurthula N, Bhagav P, Majumdar S

Theblood-ocular barriers

Author(s): Cunha-Vaz J

Drug delivery to the retina: challenges and opportunities

Author(s): Duvvuri S,Majumdar S, Mitra AK

Ocularpreparations: the formulation approach

Author(s): Kaur IP, Kanwar M

Evaluation of topical hesperetin matrix filmfor back-of-the-eye delivery

Author(s): Adelli GR, Hingorani T, PunyamurthulaN, Balguri SP, Majumdar S

Ocular inserts - Advancement in therapy of eye diseases

Author(s): Kumari A, Sharma PK, Garg VK,Garg G

Ocular inserts for topical delivery

Author(s): SaettoneFM, Salminen L

Stability of benzocaine formulated in commercialoral disintegrating tablet platforms

Author(s): Köllmer M, Popescu C, Manda P,Zhou L, Gemeinhart RA

New methods of drug delivery

Author(s): Langer R

Iontophoretic drug delivery for the treatment ofscars

Author(s): Manda P, Angamuthu M, HiremathSR, Raman V, Murthy SN

Polysulfone capillary fiber forintraocular drug delivery: in vitro and in vivo evaluations

Author(s): Rahimy MH, PeymanGA, Chin SY, Golshani R, Aras C, et al.

Intravitreal sustained-releaseganciclovir

Author(s): Smith TJ, Pearson PA, BlandfordDL, Brown JD, Goins KA, et al.

Delivery of cefotaxime to the brain viaintranasal administration

Author(s): Manda P, Hargett JK, Kiran Vaka SR,Repka MA, Narasimha Murthy S

Biodegradable Intrascleral Implant for SustainedIntraocular Delivery of Betamethasone Phosphate

Author(s): Okabe J, Kimura H, Kunou N, OkabeK, Kato A, et al.

Delivery of ziconotide to cerebrospinalfluid via intranasal pathway for the treatment of chronic pain

Author(s): Manda P, Kushwaha AS, Kundu S,Shivakumar H, Jo SB, et al.

Episcleral implants for topotecandelivery to the posterior segment of the eye

Author(s): Carcaboso AM, Chiappetta DA,Opezzo JA, Höcht C, Fandiño AC, et al.